Understand the source comparison
Orforglipron 30s Age-Specific Protocol: Comparison to Standard and Older Cohorts
| Age Cohort | Starting Dose | Escalation Interval | Time to 12mg | Nausea Incidence at 9mg | Mean Weight Loss at 24 Weeks | Professional Assessment ||—|—|—|—|—|—|| 30–39 years | 3mg daily | 4 weeks per step | 24 weeks | 35% | 9.2% | Slower titration required
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Age Cohort | Starting Dose | Escalation Interval | Time to 12mg | Nausea Incidence at 9mg | Mean Weight Loss at 24 Weeks | Professional Assessment ||—|—|—|—|—|—|| 30–39 years | 3mg daily | 4 weeks per step | 24 weeks | 35% | 9.2% | Slower titration required due to higher receptor sensitivity and faster metabolism. Extended protocol reduces discontinuation by 12 percentage points || 40–49 years | 3mg daily | 3 weeks per step | 18 weeks | 28% | 8.7% | Standard protocol works well. Moderate receptor density and gastric motility balance efficacy and tolerability || 50+ years | 6mg daily | 3 weeks per step | 15 weeks | 22% | 7.9% | Faster escalation tolerated due to lower baseline GLP-1R density and slower gastric emptying. Can start at higher dose |